• Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin 

      Olsen, Oddrun Elise; Wader, Karin Fahl; Misund, Kristine; Våtsveen, Thea Kristin; Rø, Torstein Baade; Mylin, Anne K.; Turesson, I; Størdal, Berit Fladvad; Moen, Siv Helen; Standal, Therese; Waage, Anders; Sundan, Anders; Holien, Toril (Journal article; Peer reviewed, 2014)
      Multiple myeloma is a malignancy of plasma cells predominantly located in the bone marrow. A number of bone morphogenetic proteins (BMPs) induce apoptosis in myeloma cells in vitro, and with this study we add BMP-9 to the ...
    • Caspase-8 regulates the expression of pro- and anti-inflammatory cytokines in human bone marrow-derived mesenchymal stromal cells 

      Moen, Siv Helen; Westhrin, Marita; Zahoor, Muhammad; Nikolai N., Nørgaard; Hella, Hanne; Størdal, Berit Fladvad; Sundan, Anders; Nilsen, Nadra J.; Sponaas, Anne-Marit; Standal, Therese (Journal article; Peer reviewed, 2016)
      Introduction: Mesenchymal stem cells, also called mesenchymal stromal cells, MSCs, have great potential in stem cell therapy partly due to their immunosuppressive properties. How these cells respond to chronic inflammatory ...
    • Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes 

      Westhrin, Marita; Moen, Siv Helen; Kristensen, Ida Bruun; Buene, Glenn; Mylin, Anne Kærsgaard; Turesson, Ingemar; Abildgaard, Niels; Waage, Anders; Standal, Therese (Journal article; Peer reviewed, 2018)
      Chemerin is a recently discovered adipokine shown to be involved in both inflammatory and metabolic processes. Here, we demonstrate that chemerin serum levels are elevated in patients with multiple myeloma and that it ...
    • Dickkopf-1 is associated with periarticular bone loss in patients with rheumatoid arthritis 

      Grandaunet, Berit Helen Jensen; Syversen, Silje Watterdal; Hoff, Mari; Van der Hejde, Désirée; Haugeberg, Glenn; Kvien, Tore Kristian; Standal, Therese (Journal article; Peer reviewed, 2013-11)
      Objective: To examine whether cytokines shown to suppress osteoblasts, Dickkopf-1 (DKK1) and hepatocyte growth factor (HGF), are associated with periarticular bone loss in rheumatoid arthritis (RA). Methods: RA patients ...
    • gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation 

      Standal, Therese; Johnson, Rachelle; McGregor, Narelle; Poulton, Ingrid; Ho, Patricia W M; Martin, T. John; Sims, Natalie (Journal article; Peer reviewed, 2014)
      Parathyroid hormone (PTH) treatment stimulates osteoblast differentiation and bone formation, and is the only currently approved anabolic therapy for osteoporosis. In cells of the osteoblast lineage, PTH also stimulates ...
    • Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss 

      Zahoor, Muhammad; Westhrin, Marita; Aass, Kristin Roseth; Moen, Siv Helen; Misund, Kristine; Psonka-Antonczyk, Katarzyna Maria; Giliberto, Mariaserena; Buene, Glenn; Sundan, Anders; Waage, Anders; Sponaas, Anne-Marit; Standal, Therese (Journal article; Peer reviewed, 2017)
      Multiple myeloma (MM) is a hematologic cancer characterized by expansion of malignant plasma cells in the bone marrow. Most patients develop an osteolytic bone disease, largely caused by increased osteoclastogenesis. The ...
    • IL-32 and multiple myeloma bone disease 

      Aass, Kristin Roseth (Master thesis, 2016)
      Multiple myeloma is a malignancy of plasma cells characterized by multiple tumors in the bone marrow and progressive osteolytic bone disease. The bone lesions are caused by increased bone resorption by osteoclasts and ...
    • Monitoring multiple myeloma by quantification of recurrent mutations in serum 

      Rustad, Even Holth; Coward, Eivind; Skytøen, Emilie R; Misund, Kristine; Holien, Toril; Standal, Therese; Børset, Magne; Beisvag, Vidar; Myklebost, Ola; Meza, Leonardo Zepeda; Hong, Yan Dai; Sundan, Anders; Waage, Anders (Journal article; Peer reviewed, 2017)
      Circulating tumor DNA is a promising biomarker to monitor tumor load and genome alterations. We explored the presence of circulating tumor DNA in multiple myeloma patients and its relation to disease activity during long-term ...
    • Multiple myeloma : the interplay between malignant plasma cells and the bonemarrow microenvironment 

      Standal, Therese (Dissertations at the Faculty of Medicine, 0805-7680; 2006:26272, Doctoral thesis, 2006)
      The overall objective of this work was to study how myeloma cells influence the bone marrow microenvironment in which they reside, focusing on the cells that resorb or synthesize bone. More specifically we wanted to ...
    • New players in an old game: Role of immunoglobulins in the pathogenesis of multiple myeloma 

      Kovcic, Vlado (Doctoral theses at NTNU;2020:124, Doctoral thesis, 2020)
      Multiple myeloma is a haematological malignancy characterized by uncontrolled proliferation of malignant plasma cells. The myeloma cells secrete immunoglobulins, which leads to the presence of high levels of monoclonal ...
    • Osteogenic differentiation of human mesenchymal stem cells in mineralized alginate matrices 

      Westhrin, Marita; Xie, Minli; Olderøy, Magnus Ø.; Sikorski, Pawel; Strand, Berit Løkensgard; Standal, Therese (Journal article; Peer reviewed, 2015)
      Mineralized biomaterials are promising for use in bone tissue engineering. Culturing osteogenic cells in such materials will potentially generate biological bone grafts that may even further augment bone healing. Here, ...
    • Osteogenic properties of human mesenchymal stem cells cultured on additively manufactured Ti-6Al-4V samples 

      Ouyang, Lingzi (Master thesis, 2020)
      Annually, hundreds of thousands of hip replacements are performed in the United States alone. This number is expected to increase with an increasing number of motor vehicle accidents and an increasingly active aging ...
    • PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy 

      Sponaas, Anne-Marit; Nejati Moharrami, Neda; Feyzi, Emadoldin; Standal, Therese; Rustad, Even Holth; Waage, Anders; Sundan, Anders (Peer reviewed; Journal article, 2015)
      In this study we set out to investigate whether anti PDL1 or PD–1 treatment targeting the immune system could be used against multiple myeloma. DCs are important in regulating T cell responses against tumors. We therefore ...
    • The Role of IL-32 in Multiple Myeloma 

      Aass, Kristin Roseth (Doctoral theses at NTNU;2020:256, Doctoral thesis, 2020)
    • The proportion of CD16+CD14dim monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma 

      Sponaas, Anne-Marit; Moen, Siv Helen; Liabakk, Nina-Beate; Feyzi, Emadoldin; Holien, Toril; Kvam, Solveig; Grøseth, Lill Anny Gunnes; Størdal, Berit Fladvad; Buene, Glenn; Espevik, Terje; Waage, Anders; Standal, Therese; Sundan, Anders (Journal article; Peer reviewed, 2015)
      Multiple myeloma is an incurable cancer with expansion of malignant plasma cells in the bone marrow. Previous studies have shown that monocytes and macrophages in the bone marrow milieu are important for tumor growth ...
    • Toll-like receptor-mediated regulation of IL-32 in multiple myeloma cells 

      Tryggestad, Synne Stokke (Master thesis, 2020)
      Myelomatose, eller beinmargskreft, skyldes ukontrollert vekst av maligne plasmaceller i beinmargen. Pasienter med myelomatose er spesielt utsatt for infeksjoner, som også er en utbredt dødsårsak hos disse pasientene. ...
    • Why do myeloma patients have bone disease? A historical perspective. 

      Børset, Magne; Sundan, Anders; Waage, Anders; Standal, Therese (Peer reviewed; Journal article, 2019)
      The question of how myeloma cells cause destruction of skeletal tissue has interested scientists for many years, and knowledge in this field has developed in parallel with the understanding of physiological bone remodeling. ...